(3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid | 211566-75-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S,4aR,6S,8aR)-6-[(4-carboxyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid
• CAS: 211566-75-5
• 化学式: C₁₈H₂₃NO₄
• 分子量: 317.4
• InChiKey: YVMADKYPKNLVGU-BVUBDWEXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] ESTER DERIVATIVES OF A DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AS ANALGESTICS<br/>[FR] DERIVES ESTER D'UN ACIDE DECAHYDROISOQUINOLINE-3 CARBOXYLIQUE UTILES EN TANT QU'ANALGESIQUES
  申请人：LILLY CO ELI

  公开号：WO2003091243A1

  公开（公告）日：2003-11-06

  Thus, the present invention provides compounds of formula (I) The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a neurological disorder. The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of pain or migraine.

  因此，本发明提供了化合物的公式（I）。本发明进一步提供了利用公式（I）化合物制造用于治疗神经系统疾病的药物的用途。本发明还提供了利用公式（I）化合物制造用于治疗疼痛或偏头痛的药物的用途。
• [EN] PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)-6-FLUORODECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND ESTER DERIVATIVES THEREOF<br/>[FR] COMPOSITIONS PHARMACEUTIQUES D'ACIDE 6-(2-(2H-TÉTRAZOL-5-YL)ÉTHYL)-6-FLUORODÉCAHYDROISOQUINOLÉINE-3-CARBOXYLIQUE ET DE DÉRIVÉS ESTERS DE CELUI-CI
  申请人：SEA PHARMACEUTICALS LLC

  公开号：WO2022006537A1

  公开（公告）日：2022-01-06

  6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and 6-(2-(2H-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid hydrocarbyl ester derivatives of formula are disclosed, as are pharmaceutical compositions and methods for the treatment of pain, epilepsy, convulsions, and seizures employing those compositions.

  公开了式子为6-(2-(2H-四唑-5-基)乙基)-6-氟十氢异喹啉-3-羧酸和6-(2-(2H-四唑-5-基)乙基)-6-氟十氢异喹啉-3-羧酸的烃基酯衍生物，以及使用这些化合物的药物组合物和治疗疼痛、癫痫、惊厥和抽搐的方法。
• Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
  申请人：Ornstein Leslie Paul

  公开号：US20050256155A1

  公开（公告）日：2005-11-17

  Thus, the present invention provides compounds of formula (I) The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a neurological disorder. The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of pain or migraine.

  因此，本发明提供了公式（I）的化合物。本发明还提供了使用公式（I）的化合物制造治疗神经系统疾病药物的用途。本发明还提供了使用公式（I）的化合物制造治疗疼痛或偏头痛药物的用途。
• Methods of treating neurological disorders with group I mGluR antagonists
  申请人：——

  公开号：US20030100539A1

  公开（公告）日：2003-05-29

  Compositions and uses of mGluR5 antagonists for the treatment and prevention of neurological disorders, such as Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome, are disclosed.

  本研究公开了用于治疗和预防神经系统疾病（如脆性 X、自闭症、智力迟钝、精神分裂症和唐氏综合症）的 mGluR5 拮抗剂的组成和用途。
• Use of non-competitive and selective glur5 antagonists as gultamate receptor modulating compounds
  申请人：——

  公开号：US20040048889A1

  公开（公告）日：2004-03-11

  This invention relates to the use of chemical compounds showing non-competitive and selective GluR5 antagonist or partial agonist activity for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

  本发明涉及显示非竞争性和选择性GluR5拮抗剂或部分激动剂活性的化合物用于治疗对天冬氨酸或谷氨酸受体调节有反应的疾病的用途。此外，本发明还提供了根据本发明使用的化合物，以及包含该化合物的药物组合物，以及治疗对天冬氨酸或谷氨酸受体调节有反应的疾病或紊乱或病症的方法。